Bio Green Med Solution, Inc.
BGMS evidence brief
What we can confirm
- Market Cap:
- $5.8M
What it means
What to watch
Prepared research question
What matters most for BGMS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BGMS
Bio Green Med Solution, Inc. (BGMS), formerly Cyclacel Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on developing a single oncology drug candidate, plogosertib, targeting cell cycle and mitosis control biology, with no approved products and substantial doubt about its ability to continue as a going concern [sec · filed 2025-11-26] [sec · filed 2025-11-26] [sec · filed 2025-11-26].
Key risk: Going concern risk
Market Cap
$5.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 1 clinical trial for Bio Green Med Solution, Inc..
Bio Green Med Solution, Inc. (BGMS), formerly Cyclacel Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on developing a single oncology drug candidate, plogosertib, targeting cell cycle and mitosis control biology, with no approved products and substantial doubt about its ability to continue as a going concern [sec · filed 2025-11-26] [sec · filed 2025-11-26] [sec · filed 2025-11-26].
- The company is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle and mitosis control biology, with one product candidate, plogosertib, in clinical development [sec · filed 2025-11-26] [sec_mda · as of 2025-08-14].
- As of December 31, 2024, the company had cash and cash equivalents of $3.1 million and an accumulated deficit of $439.5 million, with no expectation of significant revenue for the foreseeable future [sec · filed 2025-11-26] [sec_mda · as of 2025-04-02].
- The company has incurred losses since inception and does not currently have sufficient funds to complete development and commercialization of any drug candidates, raising substantial doubt about its ability to continue as a going concern [sec · filed 2025-11-26].
- In March 2025, the company repurchased certain assets related to plogosertib from its subsidiary Cyclacel Limited, which entered liquidation, and the subsidiary's other drug program, fadraciclib, is being marketed for sale [sec · filed 2025-11-26].
- The company's principal executive office is now located in Kuala Lumpur, Malaysia, and it retains all marketing rights worldwide to plogosertib [sec · filed 2025-11-26] [sec_mda · as of 2025-04-02].
What works
- The company retains all worldwide marketing rights to its sole product candidate, plogosertib, providing potential for full commercial value if successful [sec_mda · as of 2025-04-02].
- Plogosertib is being evaluated in a Phase 1/2 clinical trial with a Simon 2-stage design across multiple cancer types, including bladder, breast, colorectal, and lung cancers, offering a broad potential market [sec_mda · as of 2025-08-14].
- The company has a long history in cancer cell cycle biology, being a pioneer in the field, which may provide scientific expertise and intellectual property [sec · filed 2025-11-26].
What to weigh
- The company has no approved products, no revenue from product sales, and an accumulated deficit of $439.5 million as of December 31, 2024, with continued losses expected [sec · filed 2025-11-26] [sec_mda · as of 2025-04-02].
- There is substantial doubt about the company's ability to continue as a going concern, as it does not have sufficient funds to complete development of any drug candidates [sec · filed 2025-11-26].
- The company's sole focus on plogosertib creates single-asset risk, and its subsidiary's liquidation has removed the fadraciclib program, reducing pipeline diversity [sec · filed 2025-11-26].
- Clinical trials are expensive and time-consuming, and the company may not be able to raise sufficient funds to complete development or obtain regulatory approvals [sec · filed 2025-11-26].
From the filings
Quoted directly from source documents.
Company is a clinical-stage biopharmaceutical company with one product candidate in clinical development
“We are a clinical-stage biopharmaceutical company with one product candidate in clinical development currently, plogoserti”
SEC filings · November 26, 2025
Cash and cash equivalents of $3.1 million as of December 31, 2024
“As of December 31, 2024, we had cash and cash equivalents of $3.1 million”
SEC filings · November 26, 2025
Accumulated deficit of $439.5 million as of December 31, 2024
“as of December 31, 2024, we had an accumulated deficit of $439.5 million”
SEC filings · November 26, 2025
Substantial doubt about ability to continue as a going concern
“There is substantial doubt regarding our ability to continue as a going concern.”
SEC filings · November 26, 2025
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern due to insufficient funds to complete development [sec · filed 2025-11-26]
- Single-asset pipeline risk — Company is focused solely on plogosertib after liquidation of subsidiary and loss of fadraciclib program [sec · filed 2025-11-26]
- No revenue or profitability — No product sales revenue and no expectation of significant revenue for the foreseeable future [sec_mda · as of 2025-04-02]
- Clinical trial failure risk — Clinical trials are expensive, time-consuming, and may fail, leading to loss of entire investment [sec · filed 2025-11-26]
What to watch
- Progress of the Phase 1/2 clinical trial for plogosertib, including determination of RP2D and proof-of-concept cohort results [sec_mda · as of 2025-08-14]
- Ability to raise additional capital to fund ongoing operations and clinical development [sec · filed 2025-11-26]
- Impact of the deconsolidation of Cyclacel Limited and the sale of fadraciclib assets on financial statements [sec · filed 2025-11-26]
- Any partnership or licensing agreements for plogosertib, as the company seeks selective partnership arrangements [sec · filed 2025-11-26]
Sources: SEC filings · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run Bio Green Med Solution, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Bio Green Med Solution, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Bio Green Med Solution, Inc.?
Bio Green Med Solution, Inc. (BGMS), formerly Cyclacel Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on developing a single oncology drug candidate, plogosertib, targeting cell cycle and mitosis control biology, with no approved products and substantial doubt about its ability to continue as a going concern [sec · filed 2025-11-26] [sec · filed 2025-11-26] [sec · filed 2025-11-26].
Who is the CEO of Bio Green Med Solution, Inc.?
Dr. Sing Ee Wong is the chief executive officer of Bio Green Med Solution, Inc. (BGMS).
Where is Bio Green Med Solution, Inc. headquartered?
Bio Green Med Solution, Inc. (BGMS) is headquartered in Kuala Lumpur, Malaysia.
What therapeutic areas does Bio Green Med Solution, Inc. focus on?
Bio Green Med Solution, Inc. develops therapies across Neurology, Immunology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.